Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.

Lieser EA, Croghan GA, Nevala WK, Bradshaw MJ, Markovic SN, Mansfield AS.

Lung Cancer. 2013 Oct;82(1):63-8. doi: 10.1016/j.lungcan.2013.07.007. Epub 2013 Aug 12.

PMID:
23948549
2.

Is Age ≥ 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials.

Jatoi A, Allred JB, Suman VJ, Creagan ET, Croghan GA, Amatruda T, Markovic SN.

J Geriatr Oncol. 2012 Oct 1;3(4):307-311. Epub 2012 May 7.

3.

Fluctuation of systemic immunity in melanoma and implications for timing of therapy.

Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN.

Front Biosci (Elite Ed). 2012 Jan 1;4:958-75.

PMID:
22201928
4.

Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Li Y, Sun Z, Cunningham JM, Aubry MC, Wampfler JA, Croghan GA, Johnson C, Wu D, Aakre JA, Molina J, Wang L, Pankratz VS, Yang P.

Clin Cancer Res. 2011 Jun 1;17(11):3830-40. doi: 10.1158/1078-0432.CCR-10-2877.

5.
6.

Perivascular epithelioid cell neoplasm of the uterine cervix: an unusual tumor in an unusual location.

Bradshaw MJ, Folpe AL, Croghan GA.

Rare Tumors. 2010 Dec 31;2(4):e56. doi: 10.4081/rt.2010.e56.

7.

Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States.

Croghan IT, Hurt RD, Ebbert JO, Croghan GA, Polk OD, Stella PJ, Novotny PJ, Sloan J, Loprinzi CL.

Z Gesundh Wiss. 2010 Feb;18(1):59-68. Epub 2009 Aug 11.

8.

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.

Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C.

Cancer. 2010 Jul 15;116(14):3463-8. doi: 10.1002/cncr.25191.

9.

Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report.

Mateen FJ, Jatoi A, Lineberry TW, Aranguren D, Creagan ET, Croghan GA, Jett JR, Marks RS, Molina JR, Richardson RL.

Psychooncology. 2008 Jul;17(7):721-5.

10.

Second primary tumors following tobacco dependence treatments among head and neck cancer patients.

Garces YI, Schroeder DR, Nirelli LM, Croghan GA, Croghan IT, Foote RL, Hurt RD.

Am J Clin Oncol. 2007 Oct;30(5):531-9.

PMID:
17921716
11.

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:13.

12.

A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma.

Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET.

Am J Clin Oncol. 2007 Jun;30(3):303-9.

PMID:
17551310
13.

Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.

Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, Rowland KM, Bernath A, Loots ML, Le-Lindqwister NA, Tschetter LK, Garneau SC, Flynn KA, Ebbert LP, Wender DB, Loprinzi CL.

Mayo Clin Proc. 2007 Feb;82(2):186-95.

PMID:
17290726
14.

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.

Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA.

Cancer Chemother Pharmacol. 2007 Feb;59(2):207-15. Epub 2006 Jun 9.

PMID:
16763792
15.

Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.

Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN.

Cancer. 2006 Jan 15;106(2):375-82.

16.

The prevalence of weight concerns in a smoking abstinence clinical trial.

Clark MM, Hurt RD, Croghan IT, Patten CA, Novotny P, Sloan JA, Dakhil SR, Croghan GA, Wos EJ, Rowland KM, Bernath A, Morton RF, Thomas SP, Tschetter LK, Garneau S, Stella PJ, Ebbert LP, Wender DB, Loprinzi CL.

Addict Behav. 2006 Jul;31(7):1144-52. Epub 2005 Aug 30.

PMID:
16137833
17.

Effects of biochemically confirmed smoking cessation on white blood cell count.

Abel GA, Hays JT, Decker PA, Croghan GA, Kuter DJ, Rigotti NA.

Mayo Clin Proc. 2005 Aug;80(8):1022-8.

PMID:
16092581
18.

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA.

Clin Cancer Res. 2005 Mar 1;11(5):1877-83.

19.

A contest to create media messages aimed at recruiting adolescents for stop smoking programs.

Croghan IT, Campbell HM, Patten CA, Croghan GA, Schroeder DR, Novotny PJ.

J Sch Health. 2004 Oct;74(8):325-8.

PMID:
15554118
20.

Tobacco use outcomes among patients with head and neck carcinoma treated for nicotine dependence: a matched-pair analysis.

Garces YI, Schroeder DR, Nirelli LM, Croghan GA, Croghan IT, Foote RL, Hurt RD.

Cancer. 2004 Jul 1;101(1):116-24.

21.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.

Prostate. 2004 Aug 1;60(3):197-204.

PMID:
15176049
22.

Environmental tobacco smoke exposure in women with lung cancer.

de Andrade M, Ebbert JO, Wampfler JA, Miller DL, Marks RS, Croghan GA, Jatoi A, Finke EE, Sellers TA, Yang P.

Lung Cancer. 2004 Feb;43(2):127-34.

PMID:
14739032
23.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH.

Clin Cancer Res. 2003 Jul;9(7):2520-6.

24.

Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting.

Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, Mailliard JA, Ebbert LP, Swan DK, Walsh DJ, Wiesenfeld M, Levitt R, Stella P, Johnson PA, Tschetter LK, Loprinzi C.

Nicotine Tob Res. 2003 Apr;5(2):181-7.

PMID:
12745490
25.

Tobacco use outcomes among patients with lung cancer treated for nicotine dependence.

Sanderson Cox L, Patten CA, Ebbert JO, Drews AA, Croghan GA, Clark MM, Wolter TD, Decker PA, Hurt RD.

J Clin Oncol. 2002 Aug 15;20(16):3461-9.

PMID:
12177107
26.

A community-wide smoking cessation program: Quit and Win 1998 in Olmsted county.

Croghan IT, O'Hara MR, Schroeder DR, Patten CA, Croghan GA, Hays JT, Dale LC, Bowen D, Kottke T, Hurt RD.

Prev Med. 2001 Oct;33(4):229-38.

PMID:
11570825
27.

Endoscopic technique with ultrasound imaging for neurolytic celiac plexus block.

Wiersema MJ, Wong GY, Croghan GA.

Reg Anesth Pain Med. 2001 Mar-Apr;26(2):159-63. No abstract available.

PMID:
11251141
28.

Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler.

Hurt RD, Croghan GA, Wolter TD, Croghan IT, Offord KP, Williams GM, Djordjevic MV, Richie JP Jr, Jeffrey AM.

Nicotine Tob Res. 2000 Nov;2(4):327-36.

PMID:
11197312
29.

Carbidopa/levodopa for smoking cessation: a pilot study with negative results.

Hurt RD, Ahlskog JE, Croghan GA, Offord KP, Wolter TD, Croghan IT, Moyer TP.

Nicotine Tob Res. 2000 Feb;2(1):71-8.

PMID:
11072443
30.

Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels.

Hurt RD, Croghan GA, Beede SD, Wolter TD, Croghan IT, Patten CA.

Arch Pediatr Adolesc Med. 2000 Jan;154(1):31-7.

PMID:
10632247
31.

A randomized trial of naltrexone for smoking cessation.

Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD.

Addiction. 1999 Aug;94(8):1227-37.

PMID:
10615738
32.

Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer.

Villeneuve JB, Silverman MB, Alderete B, Cliby WA, Li H, Croghan GA, Podratz KC, Jenkins RB.

Genes Chromosomes Cancer. 1999 May;25(1):65-9.

PMID:
10221342
33.

Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms.

Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, Dale LC, Moyer TP.

Psychopharmacology (Berl). 1998 Nov;140(1):98-104.

PMID:
9862408
34.

Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels.

Hurt RD, Dale LC, Croghan GA, Croghan IT, Gomez-Dahl LC, Offord KP.

Mayo Clin Proc. 1998 Feb;73(2):118-25.

PMID:
9472993
35.

Prognostic factors in bladder cancer. A pathologic, immunohistochemical, and DNA flow-cytometric study.

Lopez-Beltran A, Croghan GA, Croghan I, Matilla A, Gaeta JF.

Am J Clin Pathol. 1994 Jul;102(1):109-14.

PMID:
8037155
36.

Cell and tumor markers' immunohistochemistry in transitional cell carcinoma of the bladder.

Lopez-Beltran A, Croghan GA, Croghan I, Gaeta JF.

Urol Int. 1993;50(2):61-4.

PMID:
8460449
37.

Prognostic factors in survival of bladder cancer.

Lopez-Beltran A, Croghan GA, Croghan I, Huben RP, Mettlin C, Gaeta JF.

Cancer. 1992 Aug 15;70(4):799-807.

PMID:
1643611
38.

Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study.

Hayes DF, Mesa-Tejada R, Papsidero LD, Croghan GA, Korzun AH, Norton L, Wood W, Strauchen JA, Grimes M, Weiss RB, et al.

J Clin Oncol. 1991 Jul;9(7):1113-23.

PMID:
2045853
39.

Malignant phyllodes tumor of prostate.

Löpez-Beltran A, Gaeta JF, Huben R, Croghan GA.

Urology. 1990 Feb;35(2):164-7.

PMID:
2154876
40.

Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5.

Papsidero LD, Croghan GA, Asirwatham J, Gaeta J, Abenoza P, Englander L, Valenzuela L.

Am J Pathol. 1985 Dec;121(3):451-4.

41.

Immunoaffinity isolation of ductal carcinoma antigen using monoclonal antibody F36/22.

Papsidero LD, Croghan GA, Johnson EA, Chu TM.

Mol Immunol. 1984 Oct;21(10):955-60.

PMID:
6095073
42.

Expression of ductal carcinoma antigen in breast cancer sera as defined using monoclonal antibody F36/22.

Papsidero LD, Nemoto T, Croghan GA, Chu TM.

Cancer Res. 1984 Oct;44(10):4653-7.

43.

Reactivity of monoclonal antibody F36/22 with human ovarian adenocarcinomas.

Croghan GA, Wingate MB, Gamarra M, Johnson E, Chu TM, Allen H, Valenzuela L, Tsukada Y, Papsidero LD.

Cancer Res. 1984 May;44(5):1954-62.

44.

Experimental tumoricidal effects of monoclonal antibody against solid breast tumors.

Capone PM, Papsidero LD, Croghan GA, Chu TM.

Proc Natl Acad Sci U S A. 1983 Dec;80(23):7328-32.

45.

Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22.

Croghan GA, Papsidero LD, Valenzuela LA, Nemoto T, Penetrante R, Chu TM.

Cancer Res. 1983 Oct;43(10):4980-8.

46.

Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma.

Papsidero LD, Croghan GA, O'Connell MJ, Valenzuela LA, Nemoto T, Chu TM.

Cancer Res. 1983 Apr;43(4):1741-7.

47.

Monoclonal antibody (F5) to human prostate antigen.

Papsidero LD, Croghan GA, Wang MC, Kuriyama M, Johnson EA, Valenzuela LA, Chu TM.

Hybridoma. 1983;2(2):139-47.

PMID:
6205972
48.

Human prostate epithelial cell-specific antigen.

Papsidero LD, Wang MC, Kuriyama M, Horoszewicz JS, Leong SS, Croghan GA, Valenzuela LA, Murphy GP, Chu TM.

Prog Clin Biol Res. 1981;75A:435-43. No abstract available.

PMID:
6175981

Supplemental Content

Loading ...
Support Center